Cerus Dirección

Dirección controles de criterios 3/4

El CEO de Cerus' es Obi Greenman , nombrado en Apr 2011, tiene una permanencia de 13.08 años. compensación anual total es $3.66M, compuesta por 20.9% salario y 79.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.19% de las acciones de la empresa, por valor de $3.66M. La antigüedad media del equipo directivo y de la junta directiva es de 11.3 años y 5.7 años, respectivamente.

Información clave

Obi Greenman

Chief Executive Officer (CEO)

US$3.7m

Compensación total

Porcentaje del salario del CEO	20.9%
Permanencia del CEO	13.1yrs
Participación del CEO	1.6%
Permanencia media de la dirección	11.3yrs
Promedio de permanencia en la Junta Directiva	5.7yrs

Actualizaciones recientes de la dirección

Recent updates

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 05

Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt

Apr 12

Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company

Mar 07

Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Jan 18

Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?

Oct 06

Is Cerus (NASDAQ:CERS) A Risky Investment?

Jul 07

Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

May 12

Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)

Sep 29

Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M

Aug 04

Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside

Jul 14

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Obi Greenman en comparación con los beneficios de Cerus?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$4m	US$764k	-US$37m
Sep 30 2023	n/a	n/a	-US$50m
Jun 30 2023	n/a	n/a	-US$51m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$5m	US$732k	-US$43m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$42m
Mar 31 2022	n/a	n/a	-US$49m
Dec 31 2021	US$5m	US$696k	-US$54m
Sep 30 2021	n/a	n/a	-US$60m
Jun 30 2021	n/a	n/a	-US$61m
Mar 31 2021	n/a	n/a	-US$61m
Dec 31 2020	US$5m	US$670k	-US$60m
Sep 30 2020	n/a	n/a	-US$62m
Jun 30 2020	n/a	n/a	-US$66m
Mar 31 2020	n/a	n/a	-US$69m
Dec 31 2019	US$3m	US$645k	-US$71m
Sep 30 2019	n/a	n/a	-US$71m
Jun 30 2019	n/a	n/a	-US$67m
Mar 31 2019	n/a	n/a	-US$62m
Dec 31 2018	US$3m	US$617k	-US$58m
Sep 30 2018	n/a	n/a	-US$53m
Jun 30 2018	n/a	n/a	-US$52m
Mar 31 2018	n/a	n/a	-US$56m
Dec 31 2017	US$2m	US$597k	-US$61m

Compensación vs. Mercado: La compensación total de Obi($USD5.26M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.37M).

Compensación vs. Ingresos: La compensación de Obi ha sido consistente con los resultados de la empresa en el último año.

CEO

Obi Greenman (56 yo)

13.1yrs

Permanencia

US$3,660,472

Compensación

Mr. William M. Greenman, also known as Obi, has been the Chief Executive Officer and President of Cerus Corporation since April 2011. Mr. Greenman served as the Chief Business Officer of Cerus Corporation...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
William Greenman	President	13.1yrs	US$3.66m	1.62% $ 5.8m
Kevin Green	VP of Finance & CFO	11.3yrs	US$1.46m	0.30% $ 1.1m
Vivek Jayaraman	Chief Operating Officer	4.2yrs	US$1.79m	0.43% $ 1.5m
Chrystal Jensen	Chief Legal Officer & General Counsel	11.4yrs	US$1.31m	0.24% $ 844.5k
Richard Benjamin	Chief Medical Officer	8.8yrs	US$1.34m	0.22% $ 784.1k
Laurence Corash	Co-Founder & Chief Scientific Officer	8.8yrs	US$1.72m	1.27% $ 4.5m
Lori Roll	VP of Administration & Corporate Secretary	25.3yrs	sin datos	sin datos
Matthew Notarianni	Senior Director of Investor Relations	no data	sin datos	sin datos
Lainie Corten	Vice President of Global Marketing	no data	sin datos	sin datos
Alicia Goodman	Chief Human Resources Officer	less than a year	sin datos	sin datos
Carol Moore	Senior Vice President of Regulatory Affairs	11.3yrs	US$847.11k	0.18% $ 631.7k
Jessica Hanover	Vice President of Corporate Affairs	no data	sin datos	sin datos

11.3yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CERS es experimentado (11.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
William Greenman	President	13.1yrs	US$3.66m	1.62% $ 5.8m
Franklin Witney	Independent Director	10.2yrs	US$167.60k	0.097% $ 347.5k
Eric Bjerkholt	Independent Director	5.6yrs	US$150.85k	0.055% $ 197.1k
Daniel Swisher	Independent Chairman	12.9yrs	US$200.60k	0.036% $ 129.4k
Jami K. Nachtsheim	Independent Director	5.2yrs	US$156.60k	0.059% $ 209.1k
Gail Schulze	Independent Director	16.6yrs	US$167.60k	0.045% $ 161.0k
Timothy Moore	Independent Director	5.7yrs	US$154.60k	0.035% $ 125.6k
Ann Lucena	Independent Director	2.8yrs	US$172.60k	0.013% $ 45.7k
Hua Shan	Independent Director	1.8yrs	US$82.69k	0.018% $ 62.5k

5.7yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de CERS se considera experimentada (5.6 años de antigüedad promedio).

Cerus Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Cerus Corporation, Annual General Meeting, Jun 05, 2024

Chief Medical Officer notifies of intention to sell stock

Cerus Corporation Announces the Appointment of Alicia Goodman as Chief Human Resources Officer

Chief Medical Officer exercised options and sold US$71k worth of stock

Independent Director exercised options to buy US$94k worth of stock.

Chief Medical Officer notifies of intention to sell stock

Recent updates

Consensus EPS estimates fall by 29%

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

First quarter 2024 earnings: EPS misses analyst expectations

Cerus Corporation Reiterates Earnings Guidance for the Year Ending December 31, 2024

Cerus Corporation, Annual General Meeting, Jun 05, 2024

Cerus Corporation to Report Q1, 2024 Results on May 02, 2024

Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life

Consensus EPS estimates fall by 24%, revenue upgraded

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Consensus EPS estimates upgraded to US$0.085 loss, revenue downgraded

Chief Medical Officer notifies of intention to sell stock

No longer forecast to breakeven

Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Reiterates Product Revenue Guidance for the Full Year 2024

Cerus Corporation to Report Fiscal Year 2023 Results on Mar 05, 2024

Forecast to breakeven in 2025

Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Cerus Corporation Provides Revenue Guidance for the Fiscal Year 2024

Price target decreased by 28% to US$4.13

Cerus Corporation has filed a Follow-on Equity Offering in the amount of $96.8 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Provides Product Revenue Guidance for the Full-Year 2023

Cerus Corporation to Report Q3, 2023 Results on Nov 02, 2023

Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?

Cerus Corporation Announces the Appointment of Alicia Goodman as Chief Human Resources Officer

Price target decreased by 25% to US$5.75

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cerus Corporation Revises Revenue Guidance for the Year 2023

New minor risk - Share price stability

Is Cerus (NASDAQ:CERS) A Risky Investment?

Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Consensus EPS estimates fall by 12%

No longer forecast to breakeven

Cerus Corporation Reiterates Revenue Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Officer exercised options and sold US$71k worth of stock

No longer forecast to breakeven

Cerus Corporation to Report Q4, 2022 Results on Feb 28, 2023

No longer forecast to breakeven

Cerus Corporation Provides Revenue Guidance for the Full Year 2023

Independent Director exercised options to buy US$94k worth of stock.

Price target decreased to US$8.70

No longer forecast to breakeven

Price target decreased to US$8.70

Consensus estimates of losses per share improve by 13%

Price target decreased to US$8.50

Third quarter 2022 earnings released: US$0.048 loss per share (vs US$0.072 loss in 3Q 2021)

Cerus Corporation Revises Revenue Guidance for Full Year 2022

Price target decreased to US$8.50

Cerus Corporation Announces Health Canada Approval for Intercept Blood System for Platelets with Seven-Day Storage

Cerus Corporation to Report Q3, 2022 Results on Nov 03, 2022

Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)

Chief Medical Officer notifies of intention to sell stock

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Reiterates Revenue Guidance for the Full Year 2022

Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M

Cerus Corporation to Report Q2, 2022 Results on Aug 04, 2022

Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside

Cerus Corporation Appoints Hua Shan to its Board of Directors

Is Cerus (NASDAQ:CERS) Using Debt In A Risky Way?

VP of Finance & CFO notifies of intention to sell stock

Price target decreased to US$9.40

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Revises Product Revenue Guidance for the Full Year of 2022